Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Drug Discovery
Intellectual Property
R&D Pipeline
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Cobratoxin inhibits pain-evoked discharge of neurons in thalamic parafascicular nucleus in rats: Involvement of cholinergic and serotonergic systems


Volume 54/ Issue 4 (15 September 2009)


Alpha cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application

Critical Reviews™ in Immunology
Volume 27/ Issue 4 2007


Analgesic effects of receptin, a chemically modified cobratoxin from Thailand cobra venom

Neuroscience Bulletin
September 2006


Amelioration of acute and relapsing stages of the Experimental Allergic Encephalomyelitis by Cobra Toxins

Biomedical Sciences Instrumentation
June 2006


A long-form a-neurotoxin from cobra venom produces potent opioid-independent analgesia

Acta Pharmacologica Sinica
April 2006


A short-chain a-neurotoxin from Naja naja atra produces potent cholinergic-dependent analgesia

Neuroscience Bulletin
March 2006

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
September 09, 2015
Nutra Pharma To Present at Upcoming Investment Conference

September 08, 2015
Nutra Pharma's RPI-78M Granted Orphan Drug Status by the US Food and Drug Administration for the Treatment of Juvenile Multiple Sclerosis

July 15, 2015
Nutra Pharma Announces the Submission of Their First Orphan Drug Application to the US Food and Drug Administration (FDA)

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics